Who owns ARRIVENT BIOPHARMA INC COM?
- CUSIP Number: 04272n102
Tip: Access positions for across all investors
Analyze quarterly positions in Arrivent Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Arrivent Biopharma stock
Who bought or sold ARRIVENT BIOPHARMA INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| General Catalyst Group Management | 1.5M | $27M | 100% | Mar 2024 |
|
| BlackRock | 655k | $12M | 100% | Mar 2024 |
|
| Vanguard Group | 649k | $12M | 100% | Mar 2024 |
|
| AlphaCentric Advisors | 83k | $1.5M | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 78k | $1.4M | 100% | Mar 2024 |
|
| Bank of New York Mellon | 23k | $406k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 13k | $224k | 100% | Mar 2024 |
|
| Rhumbline Advisers | 9.8k | $174k | 100% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 4.7k | $83k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 3.2k | $58k | 100% | Mar 2024 |
|
| Citigroup | 1.7k | $31k | 100% | Mar 2024 |
|
| Amalgamated Bank | 540.00 | $10k | 100% | Mar 2024 |
|